- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03471546
Early Palliative Care Intervention in Malignant Glioma
November 23, 2020 updated by: Duke University
Model of Early Palliative Care Intervention in Patients With Newly Diagnosed WHO Grade IV Malignant Glioma, a Single Arm Feasibility Study
The purpose of this research study is to determine the feasibility and acceptability of incorporating palliative care into the clinical care plans of patients newly diagnosed with malignant brain tumors.
Palliative Care is a field of medicine that focuses on providing relief from symptoms and stress related to serious illnesses.
This study will assess the feasibility of conducting a future study, and will gather data upon which to appropriately tailor the intervention and the future study design.
The statistical analysis of this study will describe 8 components that encompass each of the 4 areas of focus or "domains": acceptability, demand, implementation, and integration.
Study Overview
Detailed Description
Patients who agree to participate at their initial consultation in our clinic will receive a referral to a Palliative Care (PC) provider who is also located in our clinic and an initial appointment will be scheduled with the PC provider.
The frequency of follow-up visits with the PC provider will be at the discretion of the PC provider and the patient.
Visits with the PC and neuro-oncology providers will be scheduled on the same day whenever possible.
As part of the study, participants will be asked to complete a number of questionnaires and assessment forms at different time intervals.
These questionnaires and assessments are intended to track symptoms experienced during the course of treatment.
Total study duration is about nine months.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- The Preston Robert Tisch Brain Tumor Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ≥ 18 years of age
- Patient must have histologically confirmed, newly diagnosed WHO grade IV malignant glioma (confirmation from biopsy, sub-total, or gross-total resection)
- Tumor must be de novo grade IV malignant glioma (i.e. NOT transformed from a lower grade)
- Patient should be planning to receive standard chemoradiation (3 or 6 week protocols are acceptable)
- Treating neuro-oncologist agrees to the patient's participation in this clinical trial
- Patient should be able to read and write English
Exclusion Criteria:
- Patient who currently has a PC provider and/or is receiving hospice care or plans on initiating hospice at the time of enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Palliative care
Newly diagnosed patients will be referred to a palliative care provider in the clinic for initial consultation and follow-up during their initial treatment for WHO Grade IV malignant glioma.
Patients will be asked to complete a number of questionnaires and assessment forms at different time intervals during the course of their initial treatment.
In addition, we will ask patients' neuro-oncology providers for feedback regarding their satisfaction with the Palliative Care services provided to the patient.
|
Initial consultation and follow-up with a palliative care provider
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability: Patient satisfaction
Time Frame: 8 months
|
Mean scores obtained from patient-completed FAMCARE-P16 questionnaires.
The FAMCARE-P16 measures patient satisfaction using 16 items on a Likert scale which are summed together to produce an aggregate score of satisfaction.
It will be administered at study completion or when a patient is discharged to hospice or withdraws study participation.
|
8 months
|
Acceptability: Provider satisfaction
Time Frame: 8 months
|
The percentage of providers who respond "Always" or "Most of the time" to the question "Were you satisfied with your patient's care are the palliative care clinic?" among those providers who complete the Palliative Care Clinic (PCC) Referring Provider Satisfaction Survey upon each patient's study completion.
|
8 months
|
Acceptability: Continuation of follow-up with palliative care provider after initial consultation
Time Frame: 8 months
|
The percentage of patients who continue to follow up with their palliative care provider after initial consultation among those who receive initial consultation.
|
8 months
|
Acceptability: Continuation of follow-up with palliative care provider beyond study period
Time Frame: 8 months
|
The percentage of patients who respond "Yes" to the question "Do you plan to continue to see a palliative care provider after your participation on the study is complete?"
among those who complete the end of study questionnaires.
This question will be included in the questionnaires administered at study completion.
|
8 months
|
Demand: Time to enroll 50 patients
Time Frame: 2 years
|
The difference in months between the date the first patient is enrolled and the date the 50th patient is enrolled.
|
2 years
|
Demand: Enrollment percentage
Time Frame: 2 years
|
The percentage of patients who choose to enroll in the study among those to which the study is offered.
|
2 years
|
Implementation: Study completion percentage
Time Frame: 2 years
|
The percentage of patients who complete all study-related questionnaires and procedures among those enrolled.
|
2 years
|
Integration: Provider perception of feasibility
Time Frame: 2 years
|
The percentage of providers who respond "Yes" or "Yes with modification" to the question "Do you think that this model of early palliative care referral is feasible to integrate into the existing clinical infrastructure in your outpatient oncology clinic?" among those providers who complete the PCC Referring Provider Satisfaction Survey upon each patient's study completion.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Katherine Peters, MD, PhD, The Preston Robert Tisch Brain Tumor Center
- Principal Investigator: David Casarett, MD, MA, Palliative Care
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 16, 2018
Primary Completion (Actual)
June 17, 2019
Study Completion (Actual)
June 17, 2019
Study Registration Dates
First Submitted
March 14, 2018
First Submitted That Met QC Criteria
March 19, 2018
First Posted (Actual)
March 20, 2018
Study Record Updates
Last Update Posted (Actual)
November 24, 2020
Last Update Submitted That Met QC Criteria
November 23, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00091481
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Glioma
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Henry FriedmanCompletedGrade IV Malignant GliomaUnited States
-
Annick DesjardinsAmgenTerminated
-
Kentuckiana Cancer InstituteEisai Inc.UnknownNewly Diagnosed Supratentorial Malignant GliomaUnited States
-
AmgenCompletedGlioblastoma or Malignant GliomaUnited States, Australia, Netherlands, Germany, Spain, France
-
Duke UniversityMonteris MedicalWithdrawnGlioblastoma | Malignant Glioma of BrainUnited States
-
CellabMEDRecruitingRecurrent Malignant GliomaKorea, Republic of
-
University of ChicagoRecruitingMalignant Glioma of BrainUnited States
-
Angiochem IncCompletedRecurrent or Progressive Malignant GliomaUnited States
Clinical Trials on Palliative Care
-
Allina Health SystemCompleted
-
Massachusetts General HospitalPatient-Centered Outcomes Research InstituteRecruitingHigh Risk Acute Myeloid Leukemia | Relapsed Adult AML | Primary Refractory Acute Myeloid LeukemiaUnited States
-
Duke UniversityNational Institute of Nursing Research (NINR)CompletedHeart Diseases | Cardiovascular Diseases | Heart FailureUnited States
-
Massachusetts General HospitalAmerican Society of Clinical OncologyCompletedNon-small Cell Lung CancerUnited States
-
University of Colorado, DenverNational Institute of Nursing Research (NINR); University of California, San...CompletedParkinson Disease | Alzheimer Disease | Lewy Body Disease | Parkinsonism | Supranuclear Palsy, Progressive | Parkinsonism Vascular | Multiple System Atrophy | Corticobasal Degeneration | Frontotemporal Dementia | Primary Progressive Aphasia | Vascular DementiaUnited States
-
Vanderbilt UniversityWithdrawn
-
Herlev and Gentofte HospitalHvidovre University HospitalTerminated
-
Washington University School of MedicineCompleted
-
The Hong Kong Polytechnic UniversityHospital Authority, Hong KongCompletedPalliative Care | Renal Failure, End-stageHong Kong
-
University of CalgaryNot yet recruitingParkinson's Disease and ParkinsonismCanada